PainReform Ltd.is a clinical stage specialty pharmaceutical company. It engages in the development of products for the treatment of pain. The company's product pipeline includes PRF-110, a product based on local anesthetic ropivacaine, which is in clinical stage. PainReform Ltd.is based in Herzeliya, Israel.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-9.34M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -450.64% |
| Return on Assets (Trailing 12 Months) | -241.33% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.61 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.61 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $27.87 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-36.83 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 0.58M |
| Free Float | 0.38M |
| Market Capitalization | $0.81M |
| Average Volume (Last 20 Days) | 9.91M |
| Beta (Past 60 Months) | 0.56 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 34.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 37.28% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |